10.6084/m9.figshare.9962852.v1 Xiaohong Han Xiaohong Han Ying Han Ying Han Qiaoyun Tan Qiaoyun Tan Yu Huang Yu Huang Jianliang Yang Jianliang Yang Sheng Yang Sheng Yang Xiaohui He Xiaohui He Shengyu Zhou Shengyu Zhou Yan Song Yan Song Jinping Pi Jinping Pi Lijie Zuo Lijie Zuo Jiarui Yao Jiarui Yao Di Wu Di Wu Zhishang Zhang Zhishang Zhang Yuankai Shi Yuankai Shi MOESM9 of Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy Springer Nature 2019 CtDNA Efficacy Chemotherapy Lung adenocarcinoma 2019-10-10 08:55:24 Journal contribution https://springernature.figshare.com/articles/journal_contribution/MOESM9_of_Tracking_longitudinal_genetic_changes_of_circulating_tumor_DNA_ctDNA_in_advanced_Lung_adenocarcinoma_treated_with_chemotherapy/9962852 Additional file 9: Fifure S4. Landscape of potentially clinically actionable variants in plasma of LUAD. (A)Number of individuals for targeting therapy during chemotherapy and mutated frequency of genes. Pre (goldenrod1): patients have potential drug targets only in pre chemotherapy; Pre & Post (grey): patients have potential drug targets in pre and post chemotherapy; Post (indianred): patients have potential drug targets only in post chemotherapy). Each bar represented a category. (B) Number of individuals for targeting therapy, each bar represented a gene. (C) Variants in genes (rows) that may predict sensitivity to ERK-Signalling, PI3K/MTOR inhibitor. Vertical columns correspond to plasma samples.